# A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects

> **NCT06918366** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Brilliant Inspiration Biotherapeutics** · enrollment: 58 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Part A - single rising dose 1
- **DRUG:** Part A - single rising dose 2
- **DRUG:** Part A - single rising dose 3
- **DRUG:** Part A - single rising dose 4
- **DRUG:** Part A - single rising dose 5
- **DRUG:** Part A - single rising dose 6
- **DRUG:** Part B - mutiple rising dose 1
- **DRUG:** Part B - mutiple rising dose 2

## Key facts

- **NCT ID:** NCT06918366
- **Lead sponsor:** Brilliant Inspiration Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-05-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06918366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06918366, "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06918366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*